Open Menu

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.

Background: PPARα is a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation (FAO), angiogenesis, and inflammation. In HCC and other tumor types, PPARα signaling promotes tumor growth and also modulates the tumor immune microenvironment to suppress antitumor immunity. Amezalpat (TPST-1120) is an investigational PPARα antagonist that inhibits FAO, targeting the bioenergetic requirements of cancer cells and restoring anticancer immune pathways. HCC has the highest PPARα expression of any major tumor type. In preclinical studies of HCC, including ß-catenin activated disease, amezalpat exhibits anti-cancer activity as a single agent and demonstrates complementary efficacy in combination with PD-L1 and VEGF inhibitors. In an ongoing global randomized Phase 1b/2 study in pts with unresectable or mHCC not previously treated with systemic therapy, amezalpat in combination with atezolizumab + bevacizumab (TPST-AB) was tolerable and was associated with a clinically meaningful improvement in multiple efficacy endpoints, including overall survival (OS) and confirmed objective response rate (ORR), compared to AB alone. Here we describe a follow-up pivotal Phase 3 study to evaluate the safety and efficacy of TPST-AB vs Pbo plus AB (Pbo-AB) in pts with unresectable or mHCC (NCT06680258).

Methods: This Phase 3, global, randomized, double-blind study will enroll ~740 pts with unresectable or mHCC. Key eligibility criteria include no prior systemic therapy (prior locoregional therapy allowed), ECOG PS 0-1, Child-Pugh Class A, and measurable disease by RECIST v1.1; pts with fibrolamellar/sarcomatoid HCC, mixed cholangiocarcinoma/HCC, and untreated active HBV are not eligible. Pts will be randomized 1:1 to receive oral amezalpat 600 mg or Pbo twice daily along with the approved doses of atezolizumab and bevacizumab every 3 weeks, until unacceptable toxicity or loss of clinical benefit. Randomization will be stratified by geographic region (Asia excluding Japan vs rest of world), macrovascular invasion and/or extrahepatic spread (y/n), baseline α-fetoprotein ( < 400 vs ≥400 ng/mL), and baseline ECOG PS (0 vs 1). The primary efficacy endpoint is OS. Key secondary efficacy endpoints include progression-free survival and ORR (RECIST v1.1). Exploratory analyses will include outcome by PD-L1 expression and ß-catenin mutational status. Interim analyses for futility (30% OS events) and efficacy (70% OS events) are planned. Findings of this pivotal study will inform the efficacy and safety profile of amezalpat added to AB vs AB alone in pts with unresectable or mHCC not previously treated with systemic therapy.

Disclaimer

Author Details

Mark Yarchoan

Johns Hopkins Medicine, Baltimore, MD

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

View MoreAbstract Disclosure
open_in_new

iframe

Company Logo

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel

View Cookies
Name

cookie name

Save Settings

Download

tp53(ashish)

Author Details

Mark Yarchoan

Abstract Details

Your Privacy

Manage Consent Preferences

Essential Website Cookies

Performance and Functionality Cookies

Personalization and Analytics Cookies

Advertising Cookies and Social Media Cookies

Cookie List